Previous close | 1.5500 |
Open | 1.4000 |
Bid | 0.1500 |
Ask | 4.5000 |
Strike | 35.00 |
Expiry date | 2024-10-18 |
Day's range | 1.4000 - 1.5500 |
Contract range | N/A |
Volume | |
Open interest | 24 |
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the UBS Virtual Targeted Protein Degradation (TPD) Day, at 2:30 p.m. ET on Monday, July 15, 2024. The event will be we
Key Insights Significantly high institutional ownership implies Nurix Therapeutics' stock price is sensitive to their...
Beyond Air (XAIR) delivered earnings and revenue surprises of 23.40% and 33.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?